A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Completed · Phase 1 · NCT06422520
Conditions: Advanced Solid Tumor
At a glance
- Research payments reported, 2025
- $891,392
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 63
About the trial
- Sponsor
- BeOne Medicines
- Tested
- BGB-C354 (drug), Tislelizumab (drug)
- Dates
- Started 2024-07-08; completion 2026-05-15
- Results posted
- Not yet
This is a first-in-human, Phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-C354 alone and in combination with tislelizumab in participants with advanced solid tumors. Study details include: * The study will be conducted in 2 phases: Phase 1a (Monotherapy Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion). * The visit frequency will be approximately every 21 days during study treatment. Maximum treatment duration will be up to two years. * The study duration is estimated to be approximately 5 years.
From ClinicalTrials.gov, last updated 2026-06-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines USA, Inc. reported $891,392 in research payments for this study in 2025 (87 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Cesar A. Perez Batista, M.D. Medical Oncology · Orlando, FL
- Glenn J. Hanna, M.D. Hematology & Oncology · Boston, MA
- Ayse Ece Cali Daylan, MD Medical Oncology · Saint Louis, MO
- Siqing Fu, MD, PH D Hematology & Oncology · Houston, TX
- Ildefonso I. Rodriguez-rivera, M.D. Hematology & Oncology · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $300,127
- Next Oncology $297,603
- Florida Cancer Specialist (scri) - Fort Myers $212,083
- Washington University $60,630
- Dana Farber Mass General Brigham Cancer Care Inc $20,949
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.